Arsenic trioxide: Expanding roles for an ancient drug?

Leukemia

Volumn 18, Issue 9, 2004, Pages 1457-1459

  Ravandi, F ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; ANTINEOPLASTIC AGENT; ARSENIC TRIOXIDE; ARSENOUS ACID DERIVATIVE; ARSPHENAMINE; ASCORBIC ACID; CYCLIN DEPENDENT KINASE INHIBITOR; HEAVY METAL; INTERLEUKIN 6; LIVER ENZYME; PARAPROTEIN; PLATINUM; PROMYELOCYTIC LEUKEMIA PROTEIN; THALIDOMIDE; ORGANOARSENIC DERIVATIVE; OXIDE;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CANCER STAGING; CELL ADHESION; CELL GROWTH; CELL PROLIFERATION; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; CYTOPENIA; DEEP VEIN THROMBOSIS; DISEASE SEVERITY; DOSE TIME EFFECT RELATION; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG MECHANISM; DRUG RESPONSE; DRUG TOLERABILITY; FATIGUE; FEVER; GROWTH INHIBITION; HISTORY OF MEDICINE; HUMAN; IN VITRO STUDY; INFECTION; LEUKEMIA; LEUKEMIA CELL LINE; LIVER DYSFUNCTION; LIVER TOXICITY; MULTIPLE MYELOMA; NEUTROPENIA; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; REVIEW; SYPHILIS; TRYPANOSOMIASIS; BLOOD; NOTE; SALVAGE THERAPY; TUMOR RECURRENCE;

ANTINEOPLASTIC AGENTS; ARSENICALS; HUMANS; MULTIPLE MYELOMA; NEOPLASM RECURRENCE, LOCAL; OXIDES; SALVAGE THERAPY;

EID: 4444221348     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2403419     Document Type: Review

References (25)

1. Rousselot P, Larghero J, Arnulf B, Poupon J, Royer B, Tibi A et al. A clinical and pharmacological study of arsenic trioxide in advanced multiple myeloma patients. Leukemia, 22 July 2004 [Epub ahead of print].
2. Klaassen CD. Heavy metals and heavy-metal antagonists. In: Hardman JG, Gilman AG, Limbird LE, (eds). The Pharmacological Basis of Therapeutics. New York: McGraw-Hill, 1996, pp 1649-1672.
3. Haller JS. Therapeutic mule: the use of arsenic in the nineteenth century materia medica. Pharm Hist 1975; 17: 87-100.
4. Kwong YL, Todd D. Delicious poison: arsenic trioxide for the treatment of leukemia. Blood 1997; 89: 3487-3488.
5. Aronson SM. Arsenic and old myths. R J Med 1994; 77: 233-234.
6. Cutler EG, Bradford EH. Action of iron, cod-liver oil, and arsenic on the globular richness of blood. Am J Med Sci 1878; 75: 74-84.
7. Forkner CE, Scott TFM. Arsenic as a therapeutic agent in chronic myelogenous leukemia. JAMA 1931; 97: 3-5.
8. 3) in the treatment of acute promyelocytic leukemia (APL): II. Clinical efficacy and pharmacokinetics in relapsed patients. Blood 1997; 89: 3354-3360.
9. Soignet SL, Maslak P, Wang ZG, Jhanwar S, Calleja E, Dardashti LJ et al. Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide. N Engl J Med 1998; 339: 1341-1348.
10. Soignet SL, Frankel SR, Douer D, Tallman MS, Kantarjian H, Calleja E et al. United States multicenter study of arsenic trioxide in relapsed acute promyelocytic leukemia. J Clin Oncol 2001; 19: 3852-3860.
11. Miller Jr WH, Schipper HM, Lee JS, Singer J, Waxman S. Mechanisms of action of arsenic trioxide. Cancer Res 2002; 62: 3893-3903.
12. Novick SC, Warrell Jr RP. Arsenicals in hematologic cancers. Semin Oncol 2000; 27: 495-501.
13. Park WH, Seol JG, Kim ES, Hyun JM, Jung CW, Lee CC et al. Arsenic trioxide-mediated growth inhibition in MC/CAR myeloma cells via cell cycle arrest in association with induction of cyclin-dependent kinase inhibitor, p21, and apoptosis. Cancer Res 2000; 60: 3065-3071.
14. Rousselot P, Labaume S, Marolleau JP, Larghero J, Noguera MH, Brouet JC et al. Arsenic trioxide and melarsoprol induce apoptosis in plasma cell lines and in plasma cells from myeloma patients. Cancer Res 1999; 59: 1041-1048.
15. Hayashi T, Hideshima T, Akiyama M, Richardson P, Schlossman RL, Chauhan D et al. Arsenic trioxide inhibits growth of human multiple myeloma cells in the bone marrow microenvironment. Mol Cancer Ther 2002; 1: 851-860.
16. Liu Q, Hilsenbeck S, Gazitt Y. Arsenic trioxide-induced apoptosis in myeloma cells: p53-dependent G1 or G2/M cell cycle arrest, activation of caspase-8 or caspase-9, and synergy with APO2/TRAIL. Blood 2003; 101: 4078-4087.
17. Munshi NC, Tricot G, Desikan R, Badros A, Zangari M, Toor A et al. Clinical activity of arsenic trioxide for the treatment of multiple myeloma. Leukemia 2002; 16: 1835-1837.
18. Hussein MA, Saleh M, Ravandi F, Mason J, Rifkin R, Ellison R. Phase 2 study of arsenic trioxide in patients with relapsed or refractory multiple myeloma. Br J Haematol 2004; 125: 470-476.
19. Grad JM, Bahlis NJ, Reis I, Oshiro MM, Dalton WS, Boise LH. Ascorbic acid enhances arsenic trioxide-induced cytotoxicity in multiple myeloma cells. Blood 2001; 98: 805-813.
20. Bahlis NJ, McCafferty-Grad J, Jordan-McMurry I, Neil J, Reis I, Kharfan-Dabaja M et al. Feasibility and correlates of arsenic trioxide combined with ascorbic acid-mediated depletion of intracellular glutathione for the treatment of relapsed/refractory multiple myeloma. Clin Cancer Res 2002; 8: 3658-3668.
21. Borad M, Swift RA, Sadler K, Yang H, Berenson JR. Melphalan, arsenic trioxide and ascorbic acid (MAC) is effective in the treatment of refractory and relapsed multiple myeloma (MM). Blood 2003; 102: 235a.
22. Birch R, Schwartzberg LS, Lawrence V, Schnell FM, Tongol JM, Prill SJ et al. A phase II study of arsenic trioxide (ATO) in combination with dexamethasone (Dex) and ascorbic acid (VITC) in patients with relapsed/refractory multiple myeloma. Blood 2003; 102: 386b.
23. Au WY, Kumana CR, Kou M, Mak R, Chan GC, Lam CW et al. Oral arsenic trioxide in the treatment of relapsed acute promyelocytic leukemia. Blood 2003; 102: 407-408.
24. Lu DP, Qiu JY, Jiang B, Wang Q, Liu KY, Liu YR et al. Tetra-arsenic tetra-sulfide for the treatment of acute promyelocytic leukemia: a pilot report. Blood 2002; 99: 3136-3143.
25. Duzkale H, Jilani I, Orsolic N, Zingaro RA, Golemovic M, Giles FJ et al. In vitro activity of dimethylarsinic acid against human leukemia and multiple myeloma cell lines. Cancer Chemother Pharmacol 2003; 51: 427-432.